2
It is considered that the first properly controlled trial in history was performed by James Lind. This Scottish surgeon and ship’s doctor was the first who conducted a trial with an appropriately controlled design from a modern point of view. In 1747 when scurvy was a common disease among sailors James Lind administered different acidic substances to 12 sailors affected with scurvy to test who benefits most. Five pairs of the seamen were given vinegar, mustard and garlic purges, and elixir of vitriol. The sixth pair was given two oranges and one lemon per day and recovered within 6 days. Objective and reliable evaluation of appropriate treatments against diseases has become a great need in medical research especially in the last century. Today healthcare professionals are required to base their decisions on the highest level of evidence. Evidence based medicine aims to rationalize this decision process in medical treatment and legitimates a certain treatment - or rejects it. In the process of finding the best treatment available it became obvious that different kinds of clinical trials might not provide the same level of evidence and differences between study designs are more than trivial. Today clinical trials are currently seen to have the highest level of evidence and to be the “Gold Standard” in clinical research.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Berwick DM (2008) The science of improvement. JAMA 299: 1182–1184
Cochrane AL (1989) Archie Cochrane in his own words. Selections arranged from his 1972 introduction to “Effectiveness and Efficiency: Random Reflections on the Health Services” 1972. Control Clin Trials 10: 428–433
Schulz KF (2001 ) Assessing allocation concealment and blinding in randomised controlled trials: why bother? Evid Based Nurs 4: 4–6
Schulz KF, Grimes DA (2002) Allocation concealment in randomised trials: defending against deciphering. Lancet 359: 614–618
de Craen AJ, Roos PJ, Leonard de Vries A, et al. (1996) Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 313: 1624–1626
Chow SC, Liu J ( 1998) Design and Analysis of Clinical Trials: Concepts and Methodologies. John Wiley & Sons, New York
ICH Expert working group (1998) Statistical principles for clinical trials. In ICH Harmonized Tripartite Guideline. http://www.pmda.go.jp/ich/e/e9_98_11_30e.pdf
Kenneth LD, Charney D, Coyle JT, et al. (2002) Neuropsychopharmacology. The Fifth Generation of Progress. Lippincott Williams & Wilkins, Philadelphia
Bacchieri A, Cioppa G (2007) Fundamentals of Clinical Research. Springer Verlag
Asmar R, Hosseini H (2009) Endpoints in clinical trials: does evidence only originate from ‘hard’ or mortality endpoints? J Hypertens 27 (Suppl 2): S45–S50
O’Neill RT (1997) Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Control Clin Trials 18: 550–556; discussion 561-557
Cannon CP (1997) Clinical perspectives on the use of composite endpoints. Control Clin Trials 18: 517–529; discussion 546-519
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Wolzt, M., Aschauer, S. (2010). Clinical trials - interventional studies. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0144-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0144-5_8
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0143-8
Online ISBN: 978-3-7091-0144-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)